Evidence map›Paper›PMID 40865517›Full record

ArticleCell reports. Medicine2025

Identification and validation of intratumoral microbiome associated with sensitization to immune checkpoint inhibitors.

Junhong Chen, Yongchao Gao, Yao Chen, Quanlin Wang, Yulong Zhang, Yujing Huang, Xiaoying Xian, Dingding Zhou, Honghao Zhou, Rong Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer.Cancer drug resistance (Alhambra, Calif.) · 2026
    Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junhong ChenEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Yongchao GaoEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Yao ChenEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Quanlin WangEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Yulong ZhangEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Yujing HuangEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Xiaoying XianEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Dingding ZhouEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Honghao ZhouEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
Rong LiuEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China.
You ZouInformation and Network Center, Central South University, Changsha 410083, P.R. China. Electronic address: zouyou@csu.edu.cn.
Wei ZhangEngineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Key Laboratory of Pharmacomicrobiomics of Hunan Province, National Clinical Research Center for Geriatric Disorders, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, P.R. China; Central Laboratory of Hunan Cancer Hospital, Central South University, Changsha 410013, P.R. China. Electronic address: csuzhangwei@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a part of the commensal microbiome, the regulatory role of the intratumoral microbiome in tumor immunity is gradually revealed. However, the relationship between the intratumoral microbiome and the efficacy of immune checkpoint inhibitors (ICIs) clinical treatment remains unclear. Here, we collect RNA sequencing (RNA-seq) data and clinical information from publicly available ICIs therapy cohorts. By developing an improved bioinformatics pipeline to identify the intratumoral microbiome and performing a comprehensive association analysis, we find that the intratumoral microbiome is associated with response to ICIs and characteristics of the tumor microenvironment (TME). In vivo experiments demonstrate that intratumoral injection of Burkholderia cepacia, Priestia megaterium, or Corynebacterium kroppenstedtii, which were selected from our analysis results, would synergize with anti-PD-1 therapy to inhibit tumor growth and enhance antitumor immunity. Our findings highlight the essential role of the intratumoral microbiome in the clinical effectiveness differences of ICIs, suggesting its potential in future ICIs combination therapy.

Indexed as

Immune Checkpoint InhibitorsMicrobiotaNeoplasmsAnimalsCell Line, TumorFemaleHumansMiceTumor MicroenvironmentImmune Checkpoint Inhibitorscancer immunotherapyimmune checkpoint inhibitorsintratumoral microbiometumor microenvironment

Identifiers

PMID40865517
PMCPMC12490247

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.